MGX MGX
Company Profile ↓Company Overview
MGX (MGX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $25.21M (-51.8% YoY); net profit $-87.87M.
- Trailing 12 Months Year-on-year growth — revenue -51.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -24.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -24.95% |
| 1 Year: | -51.79% |
Stock Price Performance
| 1 Year: | -47.17% |
| 6 Months: | -18.46% |
| 3 Months: | -13.83% |
| 1 Month: | -7.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.25 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -24.9% CAGR over 5 years.
- Trading 63.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.66M | 11.34M | 12.36M | 11.16M | 20.01M | 11.51M | 4.13M | 8.51M | 8.66M | 1.25M |
| Operating Income | -17.94M | -17.96M | -22.39M | -29.03M | -16.86M | -22.38M | -27.82M | -20.99M | -22.84M | -24.59M |
| Net Income | -16.13M | -13.01M | -19.82M | -25.15M | -10.74M | -18.77M | -25.04M | -19.91M | -20.39M | -23.06M |
| Diluted EPS | -4.74 | -3.82 | -5.82 | -1.19 | -0.29 | -0.51 | -0.68 | -0.54 | -0.55 | -0.61 |
| R&D Expense | 20.13M | 22.68M | 26.84M | 31.44M | 28.32M | 26.26M | 25.14M | 22.51M | 25.28M | 19.30M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 44.76M | 52.30M | 25.21M |
| Operating Income | -78.49M | -88.90M | -96.01M |
| Net Income | -68.25M | -78.06M | -87.87M |
| Diluted EPS | -20.05 | -2.36 | -2.36 |
| R&D Expense | 94.40M | 109.18M | 94.43M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 364.84M | 324.60M | 221.10M |
| Total Equity | -74.43M | -135.58M | 234.86M | 158.60M |
| Cash & Equivalents | - | 140.60M | 27.39M | 41.72M |
| Total Liabilities | - | 149.67M | 89.74M | 62.51M |
| Current Liabilities | - | 68.86M | 37.31M | 22.93M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -91.41M | -109.07M | -88.89M |
| Investing Cash Flow | 45.73M | -88.16M | 103.53M |
| Financing Cash Flow | 1.01M | 84.01M | -356.00K |
| Capital Expenditure | -9.81M | -3.11M | -574.00K |
| Free Cash Flow | -101.22M | -112.19M | -89.47M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | -175.4% | -170.0% | -380.9% |
| Net Margin % | -152.5% | -149.3% | -348.5% |
| ROE % | 50.3% | -33.2% | -55.4% |
| ROCE % | -26.5% | -30.9% | -48.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MGX
MGX|Metagenomi Inc|Price:1.215|Chg%:+0.005 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTFBkOHU2X3lhdGFLRmF5WE85N2g2ajQ2WDFUdUF3aUdmcnFhb1ZWY0p5VTBKdEo3aHR3WllOZFVTd081bGIzdXZvTU5lNXlpZVpSbzFKdzFHVHpHVC1KcGhtUHFFR0hTN1lxQU5JRg?oc=5" target="_blank">MGX|Metagenomi Inc|Pr…
Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxQLXFKc3lsdWtoSDBNeW5vNDdGZVNoYUNoNnU1OGR3M1ZDb2gxUzVHcEN3UEdrLTBhZDJYdEt2aFZpRWNhT2dyNjZQOWZpTW5yTjZiMEthQ3RkWTlITWdGVWxQSkRNcXE0cU00STBKMHprMGRBb29qT3RQQnZLMFdfRnRnbWgyeGNkbEFuSU…
Metagenomi Therapeutics, Inc. Revenue Breakdown – NASDAQ:MGX - TradingView
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE9Rc0Rma2tvQzQ5SHM0MXo1TmNzRmM1bW5zLWZQRENDMzVVM2Z5ZTBNcC1UVjM5RnpONHgyNC1zN2RhN3dpU2ZKaXdHWkxqOFhMSzVHQU85WFM5VmtjQ2toUlJKQWZ6YXJIUmhTSWtaV1ZSM2hiYXc?oc=5" target="_blank">Metageno…
Analysts Have Lowered Expectations For Metagenomi Therapeutics, Inc. (NASDAQ:MGX) After Its Latest Results - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxNN3ZaZ3l0UFNLRGtNMVdCaUF4T1UzMU5JOHN1cTJ1ckloNXNXRTJIMXBXYnVZVWliY1FPSFVzazVRSjNMUW5YRGh6YXE4Um1pWS1ZQVZZdzE0MkV3WkZJTkVNRTVPUTRpNmMyaVlDZlpRZ3ZNdXl3UVkwN3hsTTFMX190Y01admIwT1N5dl…
MGX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE55UG8zVzdPckhPeGhCRmZ5bkIwYVNlc3pUckpxT0dtUjNMZHp3TFp3VUt1dmpWSTJUeDlnMkI1MC1GblV5U0JwdWdxN2JPcUdGWDlEWDFTUUdvZ1Q2Ql9aU2NsSFlYTVFmT09uOHlsOUlhdmJ6eFMyUQ?oc=5" target="_blank">MGX F…
The 800V power board NVIDIA is showing for next-gen AI servers - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNUjl6SE45UnVEbDVBamI0MFQzY1JoLTl5Z0ZObWx1V0JNeXZuaE50dXFTdGZVMnR1YzVwUFVHNmZZQXNrT2ZIcmoxZzdHUnJxSkF6U2J4Z20xUURiTUdpV2hkejBqWWFtWjNfZTdnZHdad2hJNE5mZ2JwLTRzczFITF9zUGFnWENNek5OcT…
MGX — Frequently Asked Questions
What is the current share price of MGX?
As of 2026-08-05 17:25 PDT, MGX trades at $1.22 on NASDAQ/NYSE. Its 52-week range is $1.14 to $3.35.
What is the P/E ratio of MGX?
MGX trades at a trailing price-to-earnings (P/E) ratio of -0.52.
What is the return on equity (ROE) of MGX?
MGX has a return on equity (ROE) of -55.40%. Its return on capital employed (ROCE) is -48.45%.
Is MGX a good stock to buy?
This page provides a data-driven analysis of MGX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.